U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C6H14N2.C2O4.Pt
Molecular Weight 397.292
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXALIPLATIN

SMILES

[Pt++].[O-]C(=O)C([O-])=O.N[C@@H]1CCCC[C@H]1N

InChI

InChIKey=ZROHGHOFXNOHSO-BNTLRKBRSA-L
InChI=1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1

HIDE SMILES / InChI
Molecular Formula C2O4
Molecular Weight 88.019
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Pt
Molecular Weight 195.084
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C6H14N2
Molecular Weight 114.1888
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Oxaliplatin (brand name Eloxatin), a new generation of platinum derivatives discovered by Prof Kidani in 1976 at Nagoya University in Japan, was licensed-in and developed by Debiopharm. Eloxatin is typically administered in combination with fluorouracil and leucovorin for the adjuvant treatment of stage III colon cancer and for the treatment of advanced carcinoma of the colon or rectum. Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo 1,2-diaminocyclohexane (DACH) platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.

CNS Activity

CNS Non-penetrant
1014
Curator's Comment: Known to be CNS non-penetrant in nonhuman primates. Human data not available

Originator

Nagoya University
1
Curator's Comment: Prof Kidani in 1976 at Nagoya University in Japan

Approval Year

2002
144
Targets

Targets

Primary TargetPharmacologyConditionPotency
DNA
278
Target ID: CHEMBL2311221
Crosslinking Agent
81
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
ELOXATIN

Approved Use

Oxaliplatin, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: •adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. •treatment of advanced colorectal cancer. Oxaliplatin injection is a platinum-based drug used in combination with infusional 5-fluorouracil/leucovorin, which is indicated for: •adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. (1) •treatment of advanced colorectal cancer. (1)

Launch Date

2002
Primary
Approved
8429
ELOXATIN

Approved Use

Oxaliplatin, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: •adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. •treatment of advanced colorectal cancer. Oxaliplatin injection is a platinum-based drug used in combination with infusional 5-fluorouracil/leucovorin, which is indicated for: •adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. (1) •treatment of advanced colorectal cancer. (1)

Launch Date

2002
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.66 μg/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/16395593
130 mg/m² 1 times / 3 weeks steady-state, intravenous
dose: 130 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
OXALIPLATIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
205.75 μg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/16395593
130 mg/m² 1 times / 3 weeks steady-state, intravenous
dose: 130 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
OXALIPLATIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
42.84 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/16395593
130 mg/m² 1 times / 3 weeks steady-state, intravenous
dose: 130 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
OXALIPLATIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
DRUG LABEL
https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00526.pdf?1265922796
PLATINUM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
130 mg/m2 single, intravenous
Dose: 130 mg/m2
Route: intravenous
Route: single
Dose: 130 mg/m2
Sources:
https://pubmed.ncbi.nlm.nih.gov/33131450
unhealthy, 56 years
n = 1
Health Status: unhealthy
Condition: colorectal cancer
Age Group: 56 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/33131450
Disc. AE: Hypersensitivity reaction...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity reaction (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/33131450
135 mg/m2 1 times / 4 weeks multiple, intravenous
Dose: 135 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 135 mg/m2, 1 times / 4 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
unhealthy, 57 years (range: 26-81 years)
n = 14
Health Status: unhealthy
Condition: advanced cancer
Age Group: 57 years (range: 26-81 years)
Sex: M+F
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
DLT: Neurotoxicity...
Dose limiting toxicities:
Neurotoxicity (50%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
150 mg/m2 1 times / 4 weeks multiple, intravenous
Dose: 150 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / 4 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
unhealthy, 57 years (range: 26-81 years)
n = 14
Health Status: unhealthy
Condition: advanced cancer
Age Group: 57 years (range: 26-81 years)
Sex: M+F
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
DLT: Neurotoxicity...
Dose limiting toxicities:
Neurotoxicity (64%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
175 mg/m2 1 times / 4 weeks multiple, intravenous
Dose: 175 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 175 mg/m2, 1 times / 4 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
unhealthy, 57 years (range: 26-81 years)
n = 7
Health Status: unhealthy
Condition: advanced cancer
Age Group: 57 years (range: 26-81 years)
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
DLT: Neurotoxicity...
Dose limiting toxicities:
Neurotoxicity (71%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
200 mg/m2 1 times / 4 weeks multiple, intravenous
Dose: 200 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 4 weeks
Co-administed with::
highest studied dose
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
unhealthy, 57 years (range: 26-81 years)
n = 5
Health Status: unhealthy
Condition: advanced cancer
Age Group: 57 years (range: 26-81 years)
Sex: M+F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
DLT: Neurotoxicity...
Dose limiting toxicities:
Neurotoxicity (100%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
55 mg/m2 multiple, intravenous
Dose: 55 mg/m2
Route: intravenous
Route: multiple
Dose: 55 mg/m2
Co-administed with::
5-fluoruracil
leucovorin
Sources:
https://pubmed.ncbi.nlm.nih.gov/33012678/
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: colon cancer
Age Group: 58 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/33012678/
Disc. AE: Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/33012678/
150 mg/m2 1 times / 3 weeks single, intravenous (total)
Dose: 150 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: single
Dose: 150 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
unhealthy, 60 years (range: 33-75 years)
n = 29
Health Status: unhealthy
Age Group: 60 years (range: 33-75 years)
Sex: M+F
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
Disc. AE: Diarrhoea...
AEs leading to
discontinuation/dose reduction:
Diarrhoea (grade 3, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
725 mg/m2 single, intravenous (total)
Dose: 725 mg/m2
Route: intravenous
Route: single
Dose: 725 mg/m2
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
unhealthy, 60 years (range: 33-75 years)
n = 29
Health Status: unhealthy
Age Group: 60 years (range: 33-75 years)
Sex: M+F
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
Disc. AE: Peripheral sensory neuropathy...
AEs leading to
discontinuation/dose reduction:
Peripheral sensory neuropathy (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
900 mg/m2 single, intravenous (total)
Dose: 900 mg/m2
Route: intravenous
Route: single
Dose: 900 mg/m2
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
unhealthy, 60 years (range: 33-75 years)
n = 29
Health Status: unhealthy
Age Group: 60 years (range: 33-75 years)
Sex: M+F
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
Disc. AE: Peripheral sensory neuropathy...
AEs leading to
discontinuation/dose reduction:
Peripheral sensory neuropathy (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
925 mg/m2 single, intravenous (total)
Dose: 925 mg/m2
Route: intravenous
Route: single
Dose: 925 mg/m2
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
unhealthy, 60 years (range: 33-75 years)
n = 29
Health Status: unhealthy
Age Group: 60 years (range: 33-75 years)
Sex: M+F
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
Disc. AE: Peripheral sensory neuropathy...
AEs leading to
discontinuation/dose reduction:
Peripheral sensory neuropathy (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
130 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 130 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 130 mg/m2, 1 times / 3 weeks
Co-administed with::
capecitabine(2000 mg/m2 for 14 days followed by 7 days of rest)
trastuzumab(initial dose of 8 mg/kg and 6 mg/kg every 21 days thereafter)
Sources:
https://pubmed.ncbi.nlm.nih.gov/32670652
unhealthy, 64 years
n = 1
Health Status: unhealthy
Condition: gastric cancer
Age Group: 64 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/32670652
Disc. AE: Lhermitte's sign...
AEs leading to
discontinuation/dose reduction:
Lhermitte's sign (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/32670652
85 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 85 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 85 mg/m2, 1 times / 2 weeks
Co-administed with::
leucovorin(200 mg/m2 intravenous infusion in 5% Dextrose Injection given over 120 minutes)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022160s012lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: advanced colorectal cancer
Age Group: adult
Sex: M
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022160s012lbl.pdf
Other AEs: Anaphylactic reaction...
Other AEs:
Anaphylactic reaction
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022160s012lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Hypersensitivity reaction 1 patient
Disc. AE
130 mg/m2 single, intravenous
Dose: 130 mg/m2
Route: intravenous
Route: single
Dose: 130 mg/m2
Sources:
https://pubmed.ncbi.nlm.nih.gov/33131450
unhealthy, 56 years
n = 1
Health Status: unhealthy
Condition: colorectal cancer
Age Group: 56 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/33131450
Neurotoxicity 50%
DLT
135 mg/m2 1 times / 4 weeks multiple, intravenous
Dose: 135 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 135 mg/m2, 1 times / 4 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
unhealthy, 57 years (range: 26-81 years)
n = 14
Health Status: unhealthy
Condition: advanced cancer
Age Group: 57 years (range: 26-81 years)
Sex: M+F
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
Neurotoxicity 64%
DLT
150 mg/m2 1 times / 4 weeks multiple, intravenous
Dose: 150 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / 4 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
unhealthy, 57 years (range: 26-81 years)
n = 14
Health Status: unhealthy
Condition: advanced cancer
Age Group: 57 years (range: 26-81 years)
Sex: M+F
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
Neurotoxicity 71%
DLT
175 mg/m2 1 times / 4 weeks multiple, intravenous
Dose: 175 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 175 mg/m2, 1 times / 4 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
unhealthy, 57 years (range: 26-81 years)
n = 7
Health Status: unhealthy
Condition: advanced cancer
Age Group: 57 years (range: 26-81 years)
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
Neurotoxicity 100%
DLT
200 mg/m2 1 times / 4 weeks multiple, intravenous
Dose: 200 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / 4 weeks
Co-administed with::
highest studied dose
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
unhealthy, 57 years (range: 26-81 years)
n = 5
Health Status: unhealthy
Condition: advanced cancer
Age Group: 57 years (range: 26-81 years)
Sex: M+F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/2295116
Thrombocytopenia 1 patient
Disc. AE
55 mg/m2 multiple, intravenous
Dose: 55 mg/m2
Route: intravenous
Route: multiple
Dose: 55 mg/m2
Co-administed with::
5-fluoruracil
leucovorin
Sources:
https://pubmed.ncbi.nlm.nih.gov/33012678/
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: colon cancer
Age Group: 58 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/33012678/
Diarrhoea grade 3, 1 patient
Disc. AE
150 mg/m2 1 times / 3 weeks single, intravenous (total)
Dose: 150 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: single
Dose: 150 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
unhealthy, 60 years (range: 33-75 years)
n = 29
Health Status: unhealthy
Age Group: 60 years (range: 33-75 years)
Sex: M+F
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
Peripheral sensory neuropathy 1 patient
Disc. AE
725 mg/m2 single, intravenous (total)
Dose: 725 mg/m2
Route: intravenous
Route: single
Dose: 725 mg/m2
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
unhealthy, 60 years (range: 33-75 years)
n = 29
Health Status: unhealthy
Age Group: 60 years (range: 33-75 years)
Sex: M+F
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
Peripheral sensory neuropathy 1 patient
Disc. AE
900 mg/m2 single, intravenous (total)
Dose: 900 mg/m2
Route: intravenous
Route: single
Dose: 900 mg/m2
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
unhealthy, 60 years (range: 33-75 years)
n = 29
Health Status: unhealthy
Age Group: 60 years (range: 33-75 years)
Sex: M+F
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
Peripheral sensory neuropathy 1 patient
Disc. AE
925 mg/m2 single, intravenous (total)
Dose: 925 mg/m2
Route: intravenous
Route: single
Dose: 925 mg/m2
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
unhealthy, 60 years (range: 33-75 years)
n = 29
Health Status: unhealthy
Age Group: 60 years (range: 33-75 years)
Sex: M+F
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/8343268
Lhermitte's sign 1 patient
Disc. AE
130 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 130 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 130 mg/m2, 1 times / 3 weeks
Co-administed with::
capecitabine(2000 mg/m2 for 14 days followed by 7 days of rest)
trastuzumab(initial dose of 8 mg/kg and 6 mg/kg every 21 days thereafter)
Sources:
https://pubmed.ncbi.nlm.nih.gov/32670652
unhealthy, 64 years
n = 1
Health Status: unhealthy
Condition: gastric cancer
Age Group: 64 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/32670652
Anaphylactic reaction
85 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 85 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 85 mg/m2, 1 times / 2 weeks
Co-administed with::
leucovorin(200 mg/m2 intravenous infusion in 5% Dextrose Injection given over 120 minutes)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022160s012lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: advanced colorectal cancer
Age Group: adult
Sex: M
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022160s012lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587
inhibitor
1767
inhibitor
1852

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP
111

CYP1A2
1524

CYP2A6
707

CYP2C19
1478

CYP2E1
882
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP
147
 no
CYP1A2
1692
 not significant
CYP2A6
739
 not significant
CYP2C19
1553
 not significant
CYP2C9
1819
 not significant
CYP2D6
1891
 not significant
CYP2E1
970
 not significant
CYP3A4
1925
 not significant
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:31941
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31941
ChemicalBook
CB1217931
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1217931
MolPort
MolPort-005-937-161
https://www.molport.com/shop/molecule-link/MolPort-005-937-161
MolPort
MolPort-006-167-572
https://www.molport.com/shop/molecule-link/MolPort-006-167-572
Selleck Chemicals
Eloxatin
http://www.selleckchem.com/products/Eloxatin.html
eMolecules
2733277
https://www.emolecules.com/cgi-bin/more?vid=2733277
eMolecules
36729906
https://www.emolecules.com/cgi-bin/more?vid=36729906
PubMed

PubMed

TitleDatePubMed
Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
2005 Feb 15
Structural basis for the sequence-dependent effects of platinum-DNA adducts.
2009 May
Recognition of platinum-DNA damage by poly(ADP-ribose) polymerase-1.
2010 Jul 27
Patents

Patents

US6306902
1

Sample Use Guides

In Vivo Use Guide
Adjuvant treatment in patients with stage III colon cancer is recommended for a total of 6 months, i.e., 12 cycles, every 2 weeks, according to the dose schedule described below for previously treated patients with advanced colorectal cancer. The recommended dose schedule given every two weeks is as follows: Day 1: ELOXATIN 85 mg/m2 IV infusion in 250-500 mL D5W and leucovorin 200 mg/m2 IV infusion in D5W both given over 120 minutes at the same time in separate bags using a Y-line, followed by 5-FU 400 mg/m2 IV bolus given over 2-4 minutes, followed by 5-FU 600 mg/m2 IV infusion in 500 mL D5W (recommended) as a 22-hour continuous infusion. Day 2: Leucovorin 200 mg/m2 IV infusion over 120 minutes, followed by 5-FU 400 mg/m2 IV bolus given over 2-4 minutes, followed by 5-FU 600 mg/m2 IV infusion in 500 mL D5W (recommended) as a 22-hour continuous infusion.
Route of Administration: Intravenous
In Vitro Use Guide
The anti-proliferative effects of oxaliplatin in human HT29 and NMG64/84 colon and COLO-357 MIA PaCa-2 and PMH2/89 pancreatic cancer cell lines and in fresh liver metastases from patients with colorectal and pancreatic cancer were investigated using the human tumor colony forming assay. Oxaliplatin significantly inhibited the colony formation in all cell lines in a concentration- and time-dependent manner. All liver tumors displayed a significant concentration-dependent inhibition of colony formation after exposure to oxaliplatin for 2 hours. The IC50 of oxaliplatin of 9 of the 10 tumors was < 10 micrograms/ml.
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:09:57 GMT 2023
Edited
by admin
on Sat Dec 16 17:09:57 GMT 2023
Record UNII
04ZR38536J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXALIPLATIN
EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
OXALIPLATIN [JAN]
Common Name English
Oxaliplatin [WHO-DD]
Common Name English
OXALIPLATIN [MART.]
Common Name English
OXALIPLATIN [USP MONOGRAPH]
Common Name English
PLATINUM, ((1R,2R)-1,2-CYCLOHEXANEDIAMINE-.KAPPA.N,.KAPPA.N')(ETHANEDIOATO(2-)-.KAPPA.O1,.KAPPA.O2)-, (SP-4-2)-
Common Name English
JM-83
Code English
Xelox component oxaliplatin
Common Name English
Folfox component oxaliplatin
Common Name English
OXALIPLATIN [VANDF]
Common Name English
OXALIPLATIN [ORANGE BOOK]
Common Name English
OXALIPLATIN [EP MONOGRAPH]
Common Name English
SR-96669
Code English
oxaliplatin [INN]
Common Name English
MBP-426 (LIPOSOMAL OXALIPLATIN)
Code English
NSC-266046
Code English
OXALIPLATIN [USP-RS]
Common Name English
OXALIPLATIN [EP IMPURITY]
Common Name English
XALIPLATIN
Brand Name English
(SP-4-2-(1R-TRANS))-(1,2-CYCLOHEXANEDIAMINE-N,N')(ETHANEDIOATO(2-)-O,O')PLATINUM
Common Name English
OXALIPLATIN [MI]
Common Name English
ELOXATIN
Brand Name English
OXALIPLATIN [USAN]
Common Name English
L-OHP
Code English
RP-54780
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 561716
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
WHO-VATC QL01XA03
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
WHO-ATC L01XA03
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
FDA ORPHAN DRUG 560816
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
FDA ORPHAN DRUG 605617
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
LIVERTOX NBK548456
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
NCI_THESAURUS C1450
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
NDF-RT N0000175073
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
NDF-RT N0000175413
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
FDA ORPHAN DRUG 69492
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
Code System Code Type Description
INN
6012
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
MESH
C030110
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
DRUG BANK
DB00526
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
CHEBI
31941
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
FDA UNII
04ZR38536J
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
IUPHAR
7433
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
DRUG CENTRAL
4210
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
RS_ITEM_NUM
1481204
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
CAS
61825-94-3
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
MERCK INDEX
m8281
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID0036760
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
DAILYMED
04ZR38536J
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
SMS_ID
100000085171
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
EVMPD
SUB09490MIG
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
NSC
266046
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
RXCUI
32592
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY RxNorm
LACTMED
Oxaliplatin
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
ChEMBL
CHEMBL414804
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
WIKIPEDIA
OXALIPLATIN
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
NCI_THESAURUS
C1181
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
USAN
KK-45
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
PUBCHEM
9887054
Created by admin on Sat Dec 16 17:09:57 GMT 2023 , Edited by admin on Sat Dec 16 17:09:57 GMT 2023
PRIMARY
Related Record Type Details
Structure of OXALIPLATIN, C14-
LABELED -> NON-LABELED
Structure of OXALIPLATIN
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
OCT-2
TRANSPORTER -> SUBSTRATE
MAY BE RESPONSIBLE FOR THE ACTIVITY OF OXALIPLATIN AGAINST against colorectal tumors
MAJOR
Structure of OXALIPLATIN
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
OCT-1
TRANSPORTER -> SUBSTRATE
MAY BE RESPONSIBLE FOR THE ACTIVITY OF OXALIPLATIN AGAINST against colorectal tumors
MAJOR
Related Record Type Details
Structure of OXALIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DIAQUODIAMINOCYCLOHEXANEPLATINUM DINITRATE, (R,R)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of OXALIPLATIN, (S,S)-
IMPURITY -> PARENT
limites not given
EP
Structure of (1,2-CYCLOHEXANEDIAMINE-N,N') DIIODIDOPLATINUM(II), (SP-4-2-(1R-TRANS))-
IMPURITY -> PARENT
Structure of (R,R-1,2-DIAMINOCYCLOHEXANE)DINITRATOPLATINUM
IMPURITY -> PARENT
Structure of DIHYDROXY OXALIPLATIN-PT(IV)
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of DIAQUODIAMINOCYCLOHEXANEPLATINUM DINITRATE, (R,R)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of DIHYDROXY OXALIPLATIN-PT(IV)
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of (SP-4-2)-Dichloro[(1R,2R)-1,2-cyclohexanediamine-κN<SUP>1</SUP>,κN<sup>2</sup>]platinum
IMPURITY -> PARENT
Structure of OXALIPLATIN, (S,S)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of OXALIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of OXALIPLATIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966